BEGIN:VCALENDAR VERSION:2.0 PRODID:-//hacksw/handcal//NONSGML v1.0//EN BEGIN:VEVENT UID:08a1c4ba548ff966983901d38abec956 DTSTAMP:20260604T214124Z DTSTART:20211111T150000 DTEND:20211111T160000 SUMMARY:The Future of Pneumonia Prevention: Building on the Success of Vaccines DESCRIPTION:Since World Pneumonia Day was established over a decade ago, global implementation of vaccines to prevent pneumonia has progressed despite disruptions caused by the COVID-19 pandemic. Delivery of pneumococcal conjugate vaccines (PCV) remains a high priority for countries as a critical tool for reducing child mortality and meeting SDG goals. Investments in scaling up and measuring the impact of PCV have helped boost the pandemic response in some countries, and countries have progressed with PCV rollouts while also introducing COVID-19 vaccines. The pandemic has progressed the successful use of mRNA vaccines to the forefront of global health and further development and attention to this platform may be beneficial for the future of PCV in low-resource settings. \n\nPanelists:\n\nArup Deb Roy, MD, Project Director, John Snow, Inc.\nKeith Klugman, MD, PhD, Director, Pneumonia, Bill & Melinda Gates Foundation\nLee Hampton, MD, Pediatrician and Medical Epidemiologist, Gavi, the Vaccine Alliance\nWangeci Kagucia, PhD, Research Fellow, KEMRI-Wellcome Trust Research Programme\n\n \nRegister here: https://jh.zoom.us/webinar/register/WN_MstuzjmrTL-YsIpfTOVJbA X-ALT-DESC;FMTTYPE=text/html:\n\n\n\n\n\n\n\n\n

Since World Pneumonia Day was established over a decade ago, global implementation of vaccines to prevent pneumonia has progressed despite disruptions caused by the COVID-19 pandemic. Delivery of pneumococcal conjugate vaccines (PCV) remains a high priority for countries as a critical tool for reducing child mortality and meeting SDG goals. Investments in scaling up and measuring the impact of PCV have helped boost the pandemic response in some countries, and countries have progressed with PCV rollouts while also introducing COVID-19 vaccines. The pandemic has progressed the successful use of mRNA vaccines to the forefront of global health and further development and attention to this platform may be beneficial for the future of PCV in low-resource settings.

Panelists:

Arup Deb Roy, MD, Project Director, John Snow, Inc.

Keith Klugman, MD, PhD, Director, Pneumonia, Bill & Melinda Gates Foundation

Lee Hampton, MD, Pediatrician and Medical Epidemiologist, Gavi, the Vaccine Alliance

Wangeci Kagucia, PhD, Research Fellow, KEMRI-Wellcome Trust Research Programme

\n\n\n LOCATION: END:VEVENT END:VCALENDAR